Title: HbA1c is a biomarker of dyslipidemia in T2DM patients
Authors: Amrendra Prasad Singh
DOI: https://dx.doi.org/10.18535/jmscr/v8i3.86
Abstract
Type 2 diabetes mellitus consists of an array of dysfunctions characterized by hyperglycemia and resulting from the combination of resistance to insulin action, inadequate insulin secretion, and excessive or inappropriate glucagon secretion. The A1C test is a blood test that provides information about a person’s average levels of blood glucose, also called blood sugar, over the past 3 months. The Aim is to study roll of HbA1c as screening biomarker of dyslipidemia in Type 2 Diabetes mellitus patients. The Study consists of 120 type 2 DM patients of 40-70 year age group along with age and sex matched healthy control. Fasting Blood samples were collected from all participants for measurement of Lipid profile, Blood sugar (FBS) and HbA1c. In case group, the mean concentration of Fasting blood glucose (mg/dl), S.Cholestrol (mg/dl), S.Triglyceride (mg/dl), S.HDL(mg/dl) and HbA1c(%) is 138.5±5.2, 265±10.5, 210.9±5.2, 38.6±6.3 and 10.6±1.0. Respectively while in control group it is 85.6±6, 156.9±8.5, 119.5±7.3, 44.5±3.2 and 5.2±0.5 respectively. The HbA1C might be used as a reliable biomarker in the screening of dyslipidemia in diabetes type- 2 patients because it showed positive correlation with TC, TG, VLDL, and LDL-C but negative correlation with HDL-C.
Keywords: HbA1c, dyslipidemia Type 2 Diabetes mellitus.
References
- Berry C, Taardif JC, Bourassa M.G; Coronary heart disease in patients with diabtes: part 1: recent advances in prevention and noninvasive management. J. AM. Coll. Cardio 2007; 49:631-42.
- Sandhu HS, Koley S, Sandhu KS; Study of correlation between Lipid Profile &Waist-Hip ratio in Diabetes Mellitus Anthropologist.2008; 10(3):215-18.
- Anjana RM, Pradeep R, Deepa M, Datta M, Sudha V, Unnikrishnan R et al.; Prevalence of diabetes and prediabetes (Impaired fasting glucose and /or impaired glucose tolerance) in urban and rural India: phase 1 results of the Indian Council of Medical Research –Indian Diabetes (ICMR=INDIAB) study: Diabetologia 2011; 54(12):3022-7.
- Chandramohan P, Mohan V; High prevalence of Diabetes and Metabolic Syndrome Among policeman JAPI 2008; 56:837-38.
- King H, Revers M; Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. Diabetes Care.1993; 16:157-77.
- Peterson KP, Pavlovich JG, Goldstein D, Little R, England J, Peterson CM; What is hemoglobin A1c?An analysis of Glycated hemoglobin’s by electospray ionization mass spectrometry. Clin Chem.1998, 2008; 44(9):1951-8.
- Sicee R, Shaw J, Zimmet P; Diabetes and impaired glucose tolerance .International Diabetes Federatio, 2006; 15-103.
- Sultan A, Thuan JF, Avignon A; Primary Prevalence of cardiovascular events and type 2 diabetes should we prioritize our interventions? Diabetes Metab.2006; 32:559-567.
- Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FI, Powe NR; Metaanalysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 14:421-431.
- Erclays F, Taneli F, Arslan B, Uslu Y; glycemic control, oxidative stress and lipid profile in children with type 1 diabetes mellitus. Arch. Med. Res 2004; 35:134-140.
- Khan HA, Sobki SH, Khan SA; Association between glycemic control and serum lipids profile in type 2 diabetic patients: HbA1C predicts dyslipidemia. Clin .Exp. Med 2007; 7:24-27.
- Wildler E; what is the consequence of an abnormal lipid profile in patients with type 2 diabetes or the metabolic syndrome? Atherosclerosis Supple; 2005; 11-14.
- Wild S, Roglic G, Green A; global prevalence of diabetes estimates for the year 2000 and projection for 2030. Diabetes Care 2004; 27:1047-1053.